000			01328cam a2200169 4500500
005			20250112040003.0
041			_afre
042			_adc
100	1	0	_aGilardoni, Aliénor _eauthor
700	1	0	_a Sarkozy, Clémentine _eauthor
245	0	0	_aBispecific antibodies and B-cell lymphoma: A new immunotherapy routinely available for patient management
260			_c2024.
500			_a63
520			_aNew therapies involving T lymphocytes are playing an increasingly important role in the management of refractory B-cell non-Hodgkin lymphoma (B-NHL), with chimeric antigen receptor T cells (CAR-T cells) available to patients as early as for second-line treatment in some cases. However, these treatments are associated with significant organizational challenges, as well as failure rates in more than half of cases. Bispecific antibodies therefore complement the therapeutic armory for B-NHL. Encouraging response rates are gradually extending their indications to the various types of B-NHL, offering a new option with the advantage of immediate availability. In this article, we summarize the current indications and recent advances of bispecific antibodies in B-NHL.
786	0		_nHématologie | 30 | 1 | 2024-06-01 | p. 46-60 | 1264-7527
856	4	1	_uhttps://shs.cairn.info/journal-hematologie-2024-1-page-46?lang=en
999			_c174728 _d174728